Physician profile
John W Bulger
NPI 1821123035
$2,537.76
in general payments reported to CMS, 2019-2025
30 companies · $955 in 2025
The $955 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52.35 · 2020: $10.98 · 2021: $109 · 2022: $315 · 2023: $476 · 2024: $619 · 2025: $955.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,050.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,050.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $459.14 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $379.86 | 2022-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $169.08 | 2023-2025 | Caplyta |
| Novo Nordisk INC | $136.63 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Exact Sciences Corporation | $116.71 | 2023-2025 | Cologuard Collection Kit |
| Almatica Pharma LLC | $112.47 | 2022-2025 | Loreev Xr, Gralise |
| Axsome Therapeutics, INC. | $112.38 | 2024-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $100.41 | 2021-2024 | Qelbree |
| Pfizer INC. | $92.63 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $92.57 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $87.70 | 2022-2025 | |
| Mylan Specialty L.P. | $79.31 | 2022-2023 | Yupelri |
| Amgen INC. | $77.71 | 2019-2022 | |
| Glaxosmithkline, LLC. | $76.43 | 2019-2024 | Trelegy Ellipta |
| Vanda Pharmaceuticals INC. | $71.89 | 2025 | Fanapt |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $61.21 | 2025 | Ohtuvayre |
| Lilly USA, LLC | $43.16 | 2025 | Mounjaro, Zepbound |
| Collegium Pharmaceutical, INC. | $32.08 | 2024-2025 | Xtampza |
| Dexcom, INC. | $30.00 | 2023 | Dexcom G6 Transmitter |
| Electromed, INC. | $28.69 | 2025 | Smartvest |
| Vertex Pharmaceuticals Incorporated | $23.72 | 2024 | |
| Alexion Pharmaceuticals, INC. | $22.71 | 2024 | Ultomiris |
| Tandem Diabetes Care, INC. | $19.23 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Neurocrine Biosciences, INC. | $19.08 | 2025 | |
| Alkermes, INC. | $18.59 | 2024 | Vivitrol |
| Astellas Pharma US INC | $18.44 | 2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.75 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.75 | 2022 | |
| Philips North America LLC | $13.58 | 2023 | |
| Ironshore Pharmaceuticals INC. | $11.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Bulger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.